ArticleJournal of experimental & clinical cancer research : CR2020

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.

Yuexian Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.